ATC Group: A10BB01 Glibenclamide

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A10BB01 in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A10 Drugs used in diabetes
3 A10B Blood glucose lowering drugs, excl. insulins
4 A10BB Sulfonamides, urea derivatives
5 A10BB01 Glibenclamide

Active ingredients in A10BB01

Active Ingredient Description

Glibenclamide, a second-generation, short half-life sulphonylurea, is a hypoglycaemic agent that reduces blood-glucose by stimulating insulin release by the pancreas. Sulphonylureas act on pancreatic beta-cells by inhibiting ATP-sensitive potassium channels.

Related product monographs

Title Information Source Document Type  
AMGLIDIA Oral suspension European Medicines Agency (EU) MPI, EU: SmPC
GLIBESYN Tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
GLITISOL Tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Albania (AL)

Australia (AU)

Austria (AT)

Croatia (HR)

Cyprus (CY)

Ecuador (EC)

Estonia (EE)

Germany (DE)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Japan (JP)

Lithuania (LT)

Malta (MT)

New Zealand (NZ)

Poland (PL)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Tunisia (TN)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.